Secondary Outcome Variables
| . | Patients of Group A With Inhalations (n = 227) . | Patients of Group B Without Inhalations (n = 155) . | Significance Level . |
|---|---|---|---|
| Fever refractory to antibiotics | 57 (25%) | 49 (32%) | P = .16 |
| Intravenous AmB | 73 (32%) | 62 (40%) | P = .11 |
| Cumulative dose of AmB (in mg) | |||
| Mean (range) | 860 (100-4,335) | 1,068 (110-4,290) | P = .16 |
| Causes of death | |||
| No death | 197 (87%) | 140 (90%) | P = .62 |
| Disease progression/noninfectious | 9 (4%) | 3 (2%) | |
| Bacterial infections | 10 (4%) | 6 (4%) | |
| Fungal infections | 9 (4%) | 5 (3%) | |
| Exact cause unknown | 2 (1%) | 1 (1%) |
| . | Patients of Group A With Inhalations (n = 227) . | Patients of Group B Without Inhalations (n = 155) . | Significance Level . |
|---|---|---|---|
| Fever refractory to antibiotics | 57 (25%) | 49 (32%) | P = .16 |
| Intravenous AmB | 73 (32%) | 62 (40%) | P = .11 |
| Cumulative dose of AmB (in mg) | |||
| Mean (range) | 860 (100-4,335) | 1,068 (110-4,290) | P = .16 |
| Causes of death | |||
| No death | 197 (87%) | 140 (90%) | P = .62 |
| Disease progression/noninfectious | 9 (4%) | 3 (2%) | |
| Bacterial infections | 10 (4%) | 6 (4%) | |
| Fungal infections | 9 (4%) | 5 (3%) | |
| Exact cause unknown | 2 (1%) | 1 (1%) |
Unless otherwise indicated, values are the number of patients, with percentages in parentheses.